

THE 5th ANNUAL 4 GIANT STEPS IN CARDIOMETABOLIC DISEASE

DYSLIPIDEMIA | HEART FAILURE
KIDNEY PROTECTION | DIABETES

SATURDAY, DECEMBER 19, 2020
9:00 AM - 11:50 AM EST

FACULTY



Ronald M. Goldenberg,
MD, FRCPC, FACE
CO-CHAIR
Consultant Endocrinologist,
LMC Diabetes & Endocrinology
Vaughan, ON, Canada



Subodh Verma,
MD, PhD, FRCSC, FAHA
CO-CHAIR
Cardiac Surgeon, St. Michael's Hospital;
Professor of Surgery and Pharmacology &
Toxicology, University of Toronto; Canada
Research Chair in Cardiovascular Surgery,
Toronto, ON, Canada



David Z. I. Cherney,
MD CM, PhD, FRCPC
Nephrologist, University Health Network
and Mount Sinai Hospital
Professor of Medicine,
University of Toronto,
Toronto, ON, Canada



Irene M. Hramiak,
MD, FRCP(C), MACP
Endocrinologist and
Site Chief of Medicine,
St. Joseph's Health Care;
Professor of Medicine,
Western University,
London, ON, Canada



Lawrence A. Leiter,
MD, FRCPC, FACP, FACE, FAHA, FACC
Endocrinologist, St. Michael's Hospital;
Professor of Medicine and Nutritional
Sciences, University of Toronto,
Toronto, ON, Canada



George Thanassoulis,
MD, MSc, FRCPC
Cardiologist and Director of Preventive
and Genomic Cardiology,
McGill University Health Centre;
Associate Professor of Medicine,
McGill University,
Montréal, QC, Canada



Shelley Zieroth,
MD, FRCPC, FCCS, FHFA, FESC, FACC
Cardiologist and Director, St. Boniface
Hospital Heart Failure and Transplant
Clinics; Head, Medical Heart Failure
Program, WRHA Cardiac Sciences
Program; Associate Professor of Medicine,
University of Manitoba; President,
Canadian Heart Failure Society;
Winnipeg, MB, Canada

AGENDA

9:00 am	Opening remarks	Dr. Ronald Goldenberg
9:05 am	The 2020 Canadian Lipid Guidelines: What's new and important?	Dr. George Thanassoulis
9:20 am	From REDUCE-IT to EVAPORATE: IPE comes of age	Dr. Subodh Verma
9:35 am	Targeting PCSK9 with monoclonal antibodies and small interfering RNAs	Dr. Lawrence Leiter
9:50 am	Panel discussion	
10:05 am	DAPA-HF and EMPEROR-Reduced: Two trials, one story	Dr. Subodh Verma
10:20 am	When and where should we use ARNIs?	Dr. Shelley Zieroth
10:35 am	Panel discussion	
10:50 am	CREDENCE, DAPA-CKD AND FIDELIO- DKD: Protecting the kidneys	Dr. David Cherney
11:05 am	GLP-1RAs for diabetes: A recap of 2020	Dr. Irene Hramiak
11:20 am	GLP-1RAs + SGLT2i combination therapy	Dr. Ronald Goldenberg
11:35 am	Panel discussion	
11:50 am	Closing remarks	Dr. Subodh Verma

LEARNING OBJECTIVES

At the conclusion of this program the Learner will be able to:

- Describe the recently updated guidelines and trial data on dyslipidemia management
- Apply current dyslipidemia guideline recommendations for primary and secondary cardiovascular risk prevention
- Explain the different types of heart failure and their pathophysiologies
- Discriminate between the available heart failure therapies based on patient characteristics and drug safety/efficacy
- Summarize the findings from contemporary kidney outcome trials and how they may impact on clinical care
- Describe the data from recently reported GLP-1RA trials
- Discuss the current guideline recommendations for selecting GLP-1RAs and SGLT2 inhibitors

This Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 2.75 Mainpro+ credits.

REGISTER AT: www.4GiantSteps.com

For more information about this program please contact S&L Solutions at
647-462-1138 or **info@slsolutionsevents.ca**

This program has been supported by educational grants from: AstraZeneca, Bayer, Boehringer Ingelheim and Eli Lilly and Company Alliance, HLS Therapeutics, Janssen, Novartis, and Novo Nordisk